China-based Jiangsu Recbio Technology Co., Ltd has announced receiving clinical trial approval from the Food and Drug Administration of the Philippines for its mRNA COVID-19 vaccine R520A. This approval marks a significant milestone in the global rollout of Recbio’s innovative vaccine targeting the Omicron variant.
Vaccine Innovation
R520A, developed by Wuhan Recogen Biotechnology Co., Ltd (a Recbio subsidiary), utilizes self-developed lyophilization technology. This technology sustains the physiochemical properties and bioactivity of mRNA-LNP, enabling long-term storage at 2℃ to 8℃. Pre-clinical studies showed high neutralizing antibody titers against the Omicron variant (4,758) and a neutralizing response against the Delta variant, highlighting its strong immunogenicity. These findings are available on the preprint server bioRxiv.
Global Context and Competitive Edge
Unlike Pfizer/BioNtech’s Comirnaty (BNT162b2) and Moderna’s Spikevax (mRNA-1273), which require ultra-low temperature storage (-80°C to -60°C), R520A’s storage conditions enhance accessibility.
Company Background
Founded in 2012, Recbio has a diverse vaccine portfolio, including candidates for HPV, COVID-19, shingles, influenza, and adult TB. Recogen, established in 2021, has developed mRNA vaccine platform technologies for designing, synthesizing, and evaluating mRNA vaccines, applying them to various infectious diseases.-Fineline Info & Tech
